Enfusion Inc (ENFN) stock saw a modest uptick, ending the day at $10.96 which represents a slight increase of $0.04 or 0.37% from the prior close of $10.92. The stock opened at $10.95 and touched a ...

NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered ...

Morgan Stanley downgraded Enfusion Inc (NYSE:ENFN) stock to "Equal-weight" from "Overweight" following Clearwater Analytics' ...

NEW YORK CITY, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between ...

Enfusion (NYSE:ENFN – Get Free Report)‘s stock had its “market perform” rating reaffirmed by equities research analysts at ...

Morgan Stanley has recently resumed Enfusion Inc (ENFN) stock to Overweight rating, as announced on May 10, 2024, according to Finviz. Earlier, on February 28, 2024, Goldman had reduced the stock from ...

Fintel reports that on January 13, 2025, William Blair downgraded their outlook for Enfusion (NYSE:ENFN) from Outperform to ...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are ...

NEW YORK, Jan. 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Enfusion, Inc. (NYSE: ENFN) to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in ...

NEW YORK & LONDON & HONG KONG, November 20, 2024--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced ...

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI ) , relating to the proposed merger with Johnson & Johnson. Under the terms of the agreement, Johnson & Johnson will acquire all outstanding shares of ...